Baxter International Inc., of Deerfield, Ill., (NYSE:BAX) and Merrimack Pharmaceuticals Inc., of Cambridge, Mass., said Baxter has submitted a marketing authorization application to the EMA for approval of MM-398 (irinotecan liposome injection), an investigational treatment for patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy.